At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma)
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Gemcitabine, and 1 other intervention for Lung Cancer and Non-small Cell Lung Cancer (NSCLC). Completed, enrolled 48 participants across 3 sites.
Detailed Summary
A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non-small Cell Lung Cancer (NSCLC)
CountriesUnited States
CollaboratorsEli Lilly and Company, Genentech, Inc.
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartJun 2006
Primary CompletionOct 2013
TodayJul 2026
First PostedMay 10, 2006
Enrollment StartJun 1, 2006
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 20.1 years ago
Interventions
Bevacizumabdrug
Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
Gemcitabinedrug
Nucleoside analog
Carboplatindrug
Alkylating agent